This document is a publication of a United States patent application (US20260085117A1) filed by Samuel Davis, Eric Smith, and Supriya Patel. The application describes antibodies, antigen-binding proteins, and Fc-fusion proteins that incorporate recombinant polypeptides with a chimeric heavy chain constant region. These constructs are designed to bind to Fc receptors while exhibiting reduced effector functions. The application also covers methods for expressing, producing, and isolating these chimeric Fc-containing proteins.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property developments in the field of antibody therapeutics. Companies involved in drug development, particularly those working with antibody-based therapies, should monitor this and related patent filings for competitive intelligence and potential licensing opportunities.